-
Full Article (HTML) (65) -
Full Article (PDF) (27)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Checklist of Responsibilities for the Scientific Editor of This Article
Publishing Process of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7292)
All Articles published online
|
Publishing Process of This Article
|
Aug 7, 2016 (publication date) through Jan 16, 2021
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Number | Cited Articles |
| 1 |
Hourieh Kalhor, Solmaz Sadeghi, Hoda Abolhasani, Reyhaneh Kalhor, Hamzeh Rahimi. Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches. Journal of Biomolecular Structure and Dynamics 2020; : 1 doi: 10.1080/07391102.2020.1824816
|
| 2 |
Kamesh Gupta, Harparam Singh Ghuman, Shivani Vijay Handa. Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile. Clinical Medicine Insights: Gastroenterology 2017; 10: 117955221772890 doi: 10.1177/1179552217728905
|
| 3 |
Fernando Magdaleno, Maximilian Joseph Brol, Robert Schierwagen, Frank Erhard Uschner, Michael Zwick, Jonel Trebicka. The Human Gut-Liver-Axis in Health and Disease. 2019; : 235 doi: 10.1007/978-3-319-98890-0_14
|
| 4 |
Elesa Poteres, Nathaniel Hubert, Sudeep Poludasu, Gabriella Brigando, Julia Moore, Kelly Keeler, Allison Isabelli, Iara Cassandra V. Ibay, Lauren Alt, Matthew Pytynia, Mae Ciancio, Kristina Martinez-Guryn. Selective Regional Alteration of the Gut Microbiota by Diet and Antibiotics. Frontiers in Physiology 2020; 11 doi: 10.3389/fphys.2020.00797
|
| 5 |
Marina Ferrer, Mònica Aguilera, Vicente Martinez. Effects of Rifaximin on Luminal and Wall-Adhered Gut Commensal Microbiota in Mice. International Journal of Molecular Sciences 2021; 22(2): 500 doi: 10.3390/ijms22020500
|
| 6 |
El-Sayed Ibrahim, Ayman Alsebaey, Hassan Zaghla, Sabry Moawad Abdelmageed, Khalid Gameel, Eman Abdelsameea. Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome. European Journal of Gastroenterology & Hepatology 2017; 29(11): 1247 doi: 10.1097/MEG.0000000000000967
|
| 7 |
Ashley Oliver, Mark Wong, Chelsea Sanchez. Role of Rifaximin in Spontaneous Bacterial Peritonitis Prevention. Southern Medical Journal 2018; 111(11): 660 doi: 10.14423/SMJ.0000000000000887
|
| 8 |
Saumya Jayakumar, Rohit Loomba. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Alimentary Pharmacology & Therapeutics 2019; 50(2): 144 doi: 10.1111/apt.15314
|
| 9 |
|
| 10 |
S. K. Zyryanov, E. A. Baybulatova. Rifaximin-Alpha and Other Crystalline Forms of Rifaximin: Are There Any Differences?. Antibiotics and Chemotherapy 2020; 65(7-8): 52 doi: 10.37489/0235-2990-2020-65-7-8-52-62
|
| 11 |
Julie Ann Tolefree, Abigail Joy Garcia, Jenee Farrell, Vik Meadows, Lindsey Kennedy, Laura Hargrove, Jennifer Demieville, Nicole Francis, Julia Mirabel, Heather Francis. Alcoholic liver disease and mast cells: What's your gut got to do with it?. Liver Research 2019; 3(1): 46 doi: 10.1016/j.livres.2019.02.002
|
| 12 |
L. S. Оrеshkо, E. A. Semenova. Clinical experience with the use of the intestinal antibiotic Rifaximin for celiac disease. Medical Council 2019; (14): 94 doi: 10.21518/2079-701X-2019-14-94-98
|
| 13 |
Peter Dellatore, Maggie Cheung, Noah Y. Mahpour, Augustine Tawadros, Vinod K. Rustgi. Clinical Manifestations of Hepatic Encephalopathy. Clinics in Liver Disease 2020; 24(2): 189 doi: 10.1016/j.cld.2020.01.010
|
| 14 |
Guilhem Royer, Fréderic Fourreau, Camille Gomart, Audrey Maurand, Bruno Hacquin, David Ducellier, Florence Cizeau, Stéphane Lo, Catherine Cordonnier-Jourdin, Mélanie Mercier-Darty, Jean-Winoc Decousser. Outbreak of an Uncommon Rifampin-resistant blaNDM-1Citrobacter amalonaticus Strain in a Digestive Rehabilitation Center: The Putative Role of Rifaximin. Clinical Infectious Diseases 2020; 71(5): 1331 doi: 10.1093/cid/ciz1172
|
| 15 |
Rommel Zerpa Alamo, Eamonn M.M. Quigley. Irritable bowel syndrome and colonic diverticular disease. Current Opinion in Gastroenterology 2019; 35(1): 27 doi: 10.1097/MOG.0000000000000499
|
| 16 |
Emma Padilla, Lluis Oms, Elena Espejo, Laura Gómez, Lurdes Pagespetit, Núria Boada, Feliu Bella, Josefa Pérez. Rifampin Resistance in Staphylococci after Rifaximin Intake for Surgical Prophylaxis in Elective Colorectal Surgery. Antimicrobial Agents and Chemotherapy 2018; 62(12) doi: 10.1128/AAC.01353-18
|